Home / Market News / $CRBP

$CRBP news and market catalysts

The 13 most recent market catalysts affecting $CRBP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

13 catalysts 5 high impact 6 bullish 4 bearish Biotechnology
Nov 14, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Raises Crescent Biopharma Price Target to $40
HC Wainwright & Co. announced an increase in its price target for Crescent Biopharma, Inc. to $40.00 per share from $36.00. This analyst upgrade reflects a more favorable view of t…
Nov 13, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Adjusts Price Target on Crescent Biopharma to $31
Wedbush Securities has raised its price target for Crescent Biopharma from $27 to $31, while reiterating its Outperform rating. This move signals increased confidence from the anal…
Nov 13, 2026 Corporate Catalyst Bearish Impact 55
Mizuho Lowers Price Target on Corbus Pharmaceuticals to $23
Mizuho Securities analyst Graig Suvannavejh lowered the price target for Corbus Pharmaceuticals (CRBP) from $24 to $23, while keeping an 'Outperform' rating. This adjustment is a r…
Nov 11, 2026 Corporate Catalyst Bearish Impact 55
RBC Capital Markets Adjusts Price Target on Corbus Pharmaceuticals
RBC Capital Markets has reduced its price target for Corbus Pharmaceuticals (CRBP) from $36 to $33. This decision comes after the company's third-quarter financial reporting and cl…
Nov 10, 2026 Corporate Catalyst Neutral Impact 75
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals reported a net loss of $37.8 million for Q3 2026, significantly wider than the $23.3 million loss in Q3 2025. This increase was primarily driven by a $15.0 m…
Sep 14, 2026 Corporate Catalyst Bullish Impact 85
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b trial for CRB-913, an oral obesity treatment. The drug demonstrated robust weight loss across a…
Sep 14, 2026 Corporate Catalyst Bullish Impact 92
Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity
Corbus Pharmaceuticals announced positive topline data from its Phase 1b trial for CRB-913, an oral, non-incretin obesity medicine. The drug demonstrated statistically significant …
Sep 11, 2026 Corporate Catalyst Bullish Impact 85
Corbus Pharmaceuticals Holdings shares are trading higher after the company announced it will host a conference call webcast on September 14 to discuss topline data for CANYON-1.
The announcement of a conference call to discuss topline data for a clinical trial is a significant corporate catalyst for a biotechnology company. Positive data could lead to a su…
Sep 11, 2026 Corporate Catalyst Neutral Impact 85
Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT
Corbus Pharmaceuticals is announcing the upcoming release of topline data for its Phase 1b CANYON-1 obesity trial for CRB-913. This is a critical juncture for the company as the da…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48
Oppenheimer analyst Jeff Jones maintained an 'Outperform' rating on Corbus Pharmaceuticals (CRBP), signaling continued confidence in the company's long-term prospects. However, the…
Aug 6, 2026 Corporate Catalyst Bearish Impact 92
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate
Corbus Pharmaceuticals (CRBP) announced Q2 EPS of $(1.81), missing analyst estimates of $(1.26) by a substantial 43.65%. This significant earnings miss is a major negative catalyst…
Aug 4, 2026 Corporate Catalyst Neutral Impact 55
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
Corbus Pharmaceuticals announced a procedural milestone in its CANYON-1 Phase 1b clinical trial for CRB-913, an obesity drug, with the last patient completing their final visit. Th…
Jul 28, 2026 Corporate Catalyst Bullish Impact 75
Corbus Pharmaceuticals Receives FDA Clearance To Start Its TEMPO-1 Registrational StudyOf CRB-701, A Nectin-4 Targeted Antibody Drug Conjugate In Second-Line Oropharyngeal Squamous Cell Carcinoma
The FDA clearance for a registrational study is a critical milestone for any pharmaceutical company, particularly for a smaller biotech like Corbus. It indicates that the FDA sees …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.